Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash from Operations: 2020-2024

Historic Cash from Operations for ARS Pharmaceuticals (SPRY) over the last 5 years, with Dec 2024 value amounting to $13.5 million.

  • ARS Pharmaceuticals' Cash from Operations fell 225.20% to -$47.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.4 million, marking a year-over-year decrease of 86.16%. This contributed to the annual value of $13.5 million for FY2024, which is 122.86% up from last year.
  • As of FY2024, ARS Pharmaceuticals' Cash from Operations stood at $13.5 million, which was up 122.86% from -$59.3 million recorded in FY2023.
  • ARS Pharmaceuticals' 5-year Cash from Operations high stood at $13.5 million for FY2024, and its period low was -$59.3 million during FY2023.
  • Over the past 3 years, ARS Pharmaceuticals' median Cash from Operations value was -$40.1 million (recorded in 2022), while the average stood at -$28.6 million.
  • In the last 5 years, ARS Pharmaceuticals' Cash from Operations plummeted by 128.22% in 2022 and then skyrocketed by 122.86% in 2024.
  • Yearly analysis of 5 years shows ARS Pharmaceuticals' Cash from Operations stood at -$31.2 million in 2020, then spiked by 43.71% to -$17.6 million in 2021, then crashed by 128.22% to -$40.1 million in 2022, then crashed by 47.88% to -$59.3 million in 2023, then surged by 122.86% to $13.5 million in 2024.